In lung and breast cancer cells, leptin treatment has amplified the levels of soluble ICAM-1 by upregulating ERK, GSK3αβ, JAK1/2, STAT3 and focal adhesion kinase (FAK) signaling [96] without affecting the expression of cell surface ICAM-1. The gene discussed is LEP; the disease is breast carcinoma.